Tohru Yoneyama1, Chikara Ohyama2, Shingo Hatakeyama1, Shintaro Narita3, Tomonori Habuchi3, Takuya Koie1, Kazuyuki Mori1, Kazuya I P J Hidari4, Maho Yamaguchi5, Takashi Suzuki5, Yuki Tobisawa1. 1. Department of Urology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki 036-8562, Japan. 2. Department of Urology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki 036-8562, Japan. Electronic address: coyama@cc.hirosaki-u.ac.jp. 3. Department of Urology , Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan. 4. Department of Food and Nutrition, Junior College Division, University of Aizu, 1-1 Aza Kadota, Oaza Yahata, Ikki-machi, Aizuwakamatsu 965-0003, Fukushima, Japan; Department of Biochemistry, University of Shizuoka, School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 442-8002, Shizuoka, Japan. 5. Department of Biochemistry, University of Shizuoka, School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 442-8002, Shizuoka, Japan.
Abstract
INTRODUCTION: We previously identified prostate cancer (PCa)-associated aberrant glycosylation of PSA, where α2,3-linked sialylation is an additional terminal N-glycan on free PSA (S2,3PSA). We then developed a new assay system measuring S2,3PSA using a magnetic microbead-based immunoassay. We compared the diagnostic accuracy of conventional PSA and percent-free PSA (%fPSA) tests. METHODS: We used MagPlex beads to measure serum S2,3PSA levels using anti-human fPSA monoclonal antibody (8A6) for capture and anti-α2,3-linked sialic acid monoclonal antibody (HYB4) for detection. We determined the cutoff values in a training test and measured serum S2,3PSA levels in 314 patients who underwent biopsy, including 138 PCa and 176 non-PCa patients with PSA of <10.0 ng/ml. Serum S2,3PSA levels were presented as mean fluorescence intensity (MFI). Receiver operating characteristic curves were used to evaluate the diagnostic accuracy of total PSA, %fPSA, and S2,3PSA. RESULTS: We determined an MFI cutoff value of 1130 with a sensitivity of 95.0% and specificity of 72.0% for the diagnosis of PCa in the training test. In the validation study, the area under the curve for the detection of PCa with S2,3PSA was 0.84, which was significantly higher than that with PSA or %fPSA. CONCLUSIONS: Although the present study is small and preliminary, these results suggest that the measurement of serum S2,3PSA using a magnetic microbead-based immunoassay may improve the accuracy of early detection of PCa and reduce unnecessary prostate biopsy.
INTRODUCTION: We previously identified prostate cancer (PCa)-associated aberrant glycosylation of PSA, where α2,3-linked sialylation is an additional terminal N-glycan on free PSA (S2,3PSA). We then developed a new assay system measuring S2,3PSA using a magnetic microbead-based immunoassay. We compared the diagnostic accuracy of conventional PSA and percent-free PSA (%fPSA) tests. METHODS: We used MagPlex beads to measure serum S2,3PSA levels using anti-human fPSA monoclonal antibody (8A6) for capture and anti-α2,3-linked sialic acid monoclonal antibody (HYB4) for detection. We determined the cutoff values in a training test and measured serum S2,3PSA levels in 314 patients who underwent biopsy, including 138 PCa and 176 non-PCa patients with PSA of <10.0 ng/ml. Serum S2,3PSA levels were presented as mean fluorescence intensity (MFI). Receiver operating characteristic curves were used to evaluate the diagnostic accuracy of total PSA, %fPSA, and S2,3PSA. RESULTS: We determined an MFI cutoff value of 1130 with a sensitivity of 95.0% and specificity of 72.0% for the diagnosis of PCa in the training test. In the validation study, the area under the curve for the detection of PCa with S2,3PSA was 0.84, which was significantly higher than that with PSA or %fPSA. CONCLUSIONS: Although the present study is small and preliminary, these results suggest that the measurement of serum S2,3PSA using a magnetic microbead-based immunoassay may improve the accuracy of early detection of PCa and reduce unnecessary prostate biopsy.
Authors: Jan Tkac; Veronika Gajdosova; Stefania Hroncekova; Tomas Bertok; Michal Hires; Eduard Jane; Lenka Lorencova; Peter Kasak Journal: Interface Focus Date: 2019-02-15 Impact factor: 3.906
Authors: Jin Song; Shiyong Ma; Lori J Sokoll; Rodrigo V Eguez; Naseruddin Höti; Hui Zhang; Phaedre Mohr; Renu Dua; Dattatraya Patil; Kristen Douglas May; Sierra Williams; Rebecca Arnold; Martin G Sanda; Daniel W Chan; Zhen Zhang Journal: Theranostics Date: 2021-04-15 Impact factor: 11.556